Eli Lilly: lung cancer drug shows positive response rate
(CercleFinance.com) - An experimental oral drug developed by Eli Lilly has showed "positive results" in patients with non-small cell lung cancer, the US company said on Monday.
In the first 105 enrolled RET-altered cancer patients with prior chemotherapy, selpercatinib treatment resulted in a 68% objective response rate, the drugmaker said.
In treatment-naïve RET fusion-positive non-small cell lung cancer patients, selpercatinib resulted in an 85% response rate in the analysis of 34 patients, it added.
Following these results, Lilly said that it is looking forward to submitting a new drug application by the end of the year.
Copyright (c) 2019 CercleFinance.com. All rights reserved.